.png)
Myasthenia Gravis Disease Market By Diagnosis, Treatment and End User - Global Industry Analysis And Forecast To 2027
Published On : October 2018 Pages : 180 Category: Pharma & Healthcare Report Code : HC101484
SEGMENTS & REGIONS:
- Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa
Myasthenia Gravis Disease Market By Diagnosis (Edrophonium Test, Imaging, Electrodiagnostic and Blood Tests), Treatment (HSCT, Medication and Surgery) and End User (Hospitals, Academic Research Institutes and Clinics) - Global Industry Analysis And Forecast To 2027
Industry Outlook
The disease of myasthenia gravis (MG) is the neuromuscular issue that develops weakness in the muscles of skeletal; those are the muscles the body utilizes for the movement. It happens when the correspondence between the muscles and the nerve cells ends up weakened. This debilitation keeps the critical muscle compressions from happening, bringing about weakness in muscles. As indicated in the reports of the Myasthenia Gravis Foundation situated in America, MG is the most widely recognized major issue of the transmission related to neuromuscular. It's a generally unique condition which affects somewhere in the range of 14 and 20 out of each 100,000 individuals in the United States. Therefore, the Myasthenia Gravis Disease Market is anticipated to expand and has tremendous scope during the forecast period. The global Myasthenia Gravis Disease Market anticipated to flourish in the future by growing at a significantly higher CAGR.
Drivers & Restrains
The driving factors of the global market are; rising numbers of initiatives by various organizations at the global level some organizations been American Autoimmune Related Diseases Association, Muscular Dystrophy Association, and other, rising occurrence of the disease in both males & females of all age groups, rising numbers of cases related to the neuromuscular disorders, increasing awareness amongst the population about the options of treatment, rise in the number of medical facilities, etc. The restraining factors of the global market are more cost of the treatment of the disorder and ignorance towards the symptoms & signs.
Regional Insights
The North American region is leading the global Myasthenia Gravis Disease Market due to rising numbers of manufactures of drugs in this region, increasing funding by the government for the disease treatment, rising awareness amongst the population about the effects of the muscle dystrophy, etc.
Myasthenia Gravis Disease Market, By Region
-
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and market share of the overall industry.
- Fresenius Kabi
- Cipla
- Valeant Pharmaceuticals International
- GlaxoSmithKline plc
- Sun Pharmaceuticals Industries Ltd.
- Piramal Healthcare
- AbbVie Inc.
- Novartis Pharmaceuticals Corporation
- Biogen Inc.
- Apotex Corporation
- Bristol-Myers Squibb Company
- Teva Pharmaceutical Industries Ltd.
- F. Hoffmann Roche La Ltd.
- RPG Life Sciences
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
o Myasthenia Gravis Disease Market, By Diagnosis, Estimates and Forecast, 2017-2027 ($Million)
o Edrophonium Test
o Imaging
o Electrodiagnostic
o Blood Tests
o Myasthenia Gravis Disease Market, By Treatment, Estimates and Forecast, 2017-2027 ($Million)
o HSCT
o Medication
o Surgery
o Myasthenia Gravis Disease Market, By End User, Estimates and Forecast, 2017-2027 ($Million)
o Hospitals
o Academic Research Institutes
o Clinics
o Myasthenia Gravis Disease Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Myasthenia Gravis Disease Market, By Country
o U.S. Myasthenia Gravis Disease Market
o Canada Myasthenia Gravis Disease Market
o Mexico Myasthenia Gravis Disease Market
o Europe
§ Europe Myasthenia Gravis Disease Market, By Country
o Germany Myasthenia Gravis Disease Market
o UK Myasthenia Gravis Disease Market
o France Myasthenia Gravis Disease Market
o Russia Myasthenia Gravis Disease Market
o Italy Myasthenia Gravis Disease Market
o Rest of Europe Myasthenia Gravis Disease Market
o Asia-Pacific
§ Asia-Pacific Myasthenia Gravis Disease Market, By Country
o China Myasthenia Gravis Disease Market
o Japan Myasthenia Gravis Disease Market
o South Korea Myasthenia Gravis Disease Market
o India Myasthenia Gravis Disease Market
o Southeast Asia Myasthenia Gravis Disease Market
o Rest of Asia-Pacific Myasthenia Gravis Disease Market
o South America
§ South America Myasthenia Gravis Disease Market, By Country
o Brazil Myasthenia Gravis Disease Market
o Argentina Myasthenia Gravis Disease Market
o Columbia Myasthenia Gravis Disease Market
o Rest of South America Myasthenia Gravis Disease Market
o Middle East and Africa
§ Middle East and Africa Myasthenia Gravis Disease Market, By Country
o Saudi Arabia Myasthenia Gravis Disease Market
o UAE Myasthenia Gravis Disease Market
o Egypt Myasthenia Gravis Disease Market
o Nigeria Myasthenia Gravis Disease Market
o South Africa Myasthenia Gravis Disease Market
o Rest of MEA Myasthenia Gravis Disease Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. SWOT Analysis
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Myasthenia Gravis Disease Market, By Diagnosis
5.1. Introduction
5.2. Global Myasthenia Gravis Disease Revenue and Market Share by Diagnosis (2017-2027)
5.2.1. Global Myasthenia Gravis Disease Revenue and Revenue Share by Diagnosis (2017-2027)
5.3. Edrophonium Test
5.3.1. Global Edrophonium Test Revenue and Growth Rate (2017-2027)
5.4. Imaging
5.4.1. Global Imaging Revenue and Growth Rate (2017-2027)
5.5. Electrodiagnostic
5.5.1. Global Electrodiagnostic Revenue and Growth Rate (2017-2027)
5.6. Blood Tests
5.6.1. Global Blood Tests Revenue and Growth Rate (2017-2027)
6. Myasthenia Gravis Disease Market, By Treatment
6.1. Introduction
6.2. Global Myasthenia Gravis Disease Revenue and Market Share by Treatment (2017-2027)
6.2.1. Global Myasthenia Gravis Disease Revenue and Revenue Share by Treatment (2017-2027)
6.3. HSCT
6.3.1. Global HSCT Revenue and Growth Rate (2017-2027)
6.4. Medication
6.4.1. Global Medication Revenue and Growth Rate (2017-2027)
6.5. Surgery
6.5.1. Global Surgery Revenue and Growth Rate (2017-2027)
7. Myasthenia Gravis Disease Market, By End User
7.1. Introduction
7.2. Global Myasthenia Gravis Disease Revenue and Market Share by End User (2017-2027)
7.2.1. Global Myasthenia Gravis Disease Revenue and Revenue Share by End User (2017-2027)
7.3. Hospitals
7.3.1. Global Hospitals Revenue and Growth Rate (2017-2027)
7.4. Academic Research Institutes
7.4.1. Global Academic Research Institutes Revenue and Growth Rate (2017-2027)
7.5. Clinics
7.5.1. Global Clinics Revenue and Growth Rate (2017-2027)
8. Myasthenia Gravis Disease Market, By Region
8.1. Introduction
8.2. Global Myasthenia Gravis Disease Revenue and Market Share by Regions
8.2.1. Global Myasthenia Gravis Disease Revenue by Regions (2017-2027)
8.3. North America Myasthenia Gravis Disease by Countries
8.3.1. North America Myasthenia Gravis Disease Revenue and Growth Rate (2017-2027)
8.3.2. North America Myasthenia Gravis Disease Revenue (Million USD) by Countries (2017-2027)
8.3.3. United States
8.3.3.1. United States Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2027)
8.3.4. Canada
8.3.4.1. Canada Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2027)
8.3.5. Mexico
8.3.5.1. Mexico Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2027)
8.4. Europe Myasthenia Gravis Disease by Countries
8.4.1. Europe Myasthenia Gravis Disease Revenue and Growth Rate (2017-2027)
8.4.2. Europe Myasthenia Gravis Disease Revenue (Million USD) by Countries (2017-2027)
8.4.3. Germany
8.4.3.1. Germany Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.4. France
8.4.4.1. France Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.5. UK
8.4.5.1. UK Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.6. Russia
8.4.6.1. Russia Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.7. Italy
8.4.7.1. Italy Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.8. Rest of Europe
8.4.8.1. Rest of Europe Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2027)
8.5. Asia-Pacific Myasthenia Gravis Disease by Countries
8.5.1. Asia-Pacific Myasthenia Gravis Disease Revenue and Growth Rate (2017-2027)
8.5.2. Asia-Pacific Myasthenia Gravis Disease Revenue (Million USD) by Countries (2017-2027)
8.5.3. China
8.5.3.1. China Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.4. Japan
8.5.4.1. Japan Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.5. Korea
8.5.5.1. Korea Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.6. India
8.5.6.1. India Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.7. Southeast Asia
8.5.7.1. Southeast Asia Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.8. Rest of Asia-Pacific
8.5.8.1. Rest of Asia-Pacific Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2027)
8.6. South America Myasthenia Gravis Disease by Countries
8.6.1. South America Myasthenia Gravis Disease Revenue and Growth Rate (2017-2027)
8.6.2. South America Myasthenia Gravis Disease Revenue (Million USD) by Countries (2017-2027)
8.6.3. Brazil
8.6.3.1. Brazil Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.4. Argentina
8.6.4.1. Argentina Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.5. Columbia
8.6.5.1. Columbia Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.6. Rest of South America
8.6.6.1. Rest of South America Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2027)
8.7. Middle East and Africa Myasthenia Gravis Disease by Countries
8.7.1. Middle East and Africa Myasthenia Gravis Disease Revenue and Growth Rate (2017-2027)
8.7.2. Middle East and Africa Myasthenia Gravis Disease Revenue (Million USD) by Countries (2017-2027)
8.7.3. Saudi Arabia
8.7.3.1. Saudi Arabia Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.4. United Arab Emirates
8.7.4.1. United Arab Emirates Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.5. Egypt
8.7.5.1. Egypt Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.6. Nigeria
8.7.6.1. Nigeria Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.7. South Africa
8.7.7.1. South Africa Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.8. Turkey
8.7.8.1. Turkey Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.9. Rest of Middle East and Africa
8.7.9.1. Rest of Middle East and Africa Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2027)
9. Company Profiles
9.1. Fresenius Kabi
9.1.1. Business Overview
9.1.2. Service Portfolio
9.1.3. Strategic Developments
9.1.4. Revenue and Market Share
9.2. Cipla
9.2.1. Business Overview
9.2.2. Service Portfolio
9.2.3. Strategic Developments
9.2.4. Revenue and Market Share
9.3. Valeant Pharmaceuticals International
9.3.1. Business Overview
9.3.2. Service Portfolio
9.3.3. Strategic Developments
9.3.4. Revenue and Market Share
9.4. GlaxoSmithKline plc
9.4.1. Business Overview
9.4.2. Service Portfolio
9.4.3. Strategic Developments
9.4.4. Revenue and Market Share
9.5. Sun Pharmaceuticals Industries Ltd.
9.5.1. Business Overview
9.5.2. Service Portfolio
9.5.3. Strategic Developments
9.5.4. Revenue and Market Share
9.6. Piramal Healthcare
9.6.1. Business Overview
9.6.2. Service Portfolio
9.6.3. Strategic Developments
9.6.4. Revenue and Market Share
9.7. AbbVie Inc.
9.7.1. Business Overview
9.7.2. Service Portfolio
9.7.3. Strategic Developments
9.7.4. Revenue and Market Share
9.8. Novartis Pharmaceuticals Corporation
9.8.1. Business Overview
9.8.2. Service Portfolio
9.8.3. Strategic Developments
9.8.4. Revenue and Market Share
9.9. Biogen Inc.
9.9.1. Business Overview
9.9.2. Service Portfolio
9.9.3. Strategic Developments
9.9.4. Revenue and Market Share
9.10. Apotex Corporation
9.10.1. Business Overview
9.10.2. Service Portfolio
9.10.3. Strategic Developments
9.10.4. Revenue and Market Share
9.11. Bristol-Myers Squibb Company
9.11.1. Business Overview
9.11.2. Service Portfolio
9.11.3. Strategic Developments
9.11.4. Revenue and Market Share
9.12. Teva Pharmaceutical Industries Ltd.
9.12.1. Business Overview
9.12.2. Service Portfolio
9.12.3. Strategic Developments
9.12.4. Revenue and Market Share
9.13. F. Hoffmann Roche La Ltd.
9.13.1. Business Overview
9.13.2. Service Portfolio
9.13.3. Strategic Developments
9.13.4. Revenue and Market Share
9.14. RPG Life Sciences
9.14.1. Business Overview
9.14.2. Service Portfolio
9.14.3. Strategic Developments
9.14.4. Revenue and Market Share
10. Global Myasthenia Gravis Disease Market Competition, by Manufacturer
10.1. Global Myasthenia Gravis Disease Revenue and Market Share by Manufacturer (2017-2017)
10.2. Global Myasthenia Gravis Disease Price By Region (2017-2017)
10.3. Top 5 Myasthenia Gravis Disease Manufacturer Market Share
10.4. Market Competition Trend
11. Myasthenia Gravis Disease Market Forecast (2017-2027)
11.1. Global Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2027)
11.2. Myasthenia Gravis Disease Market Forecast by Regions (2017-2027)
11.2.1. North America Myasthenia Gravis Disease Market Forecast (2017-2027)
11.2.1.1. United States Myasthenia Gravis Disease Market Forecast (2017-2027)
11.2.1.2. Canada Myasthenia Gravis Disease Market Forecast (2017-2027)
11.2.1.3. Mexico Myasthenia Gravis Disease Market Forecast (2017-2027)
11.2.2. Europe Myasthenia Gravis Disease Market Forecast (2017-2027)
11.2.2.1. Germany Myasthenia Gravis Disease Market Forecast (2017-2027)
11.2.2.2. France Myasthenia Gravis Disease Market Forecast (2017-2027)
11.2.2.3. UK Myasthenia Gravis Disease Market Forecast (2017-2027)
11.2.2.4. Russia Myasthenia Gravis Disease Market Forecast (2017-2027)
11.2.2.5. Italy Myasthenia Gravis Disease Market Forecast (2017-2027)
11.2.2.6. Rest of Europe Myasthenia Gravis Disease Market Forecast (2017-2027)
11.2.3. Asia-Pacific Myasthenia Gravis Disease Market Forecast (2017-2027)
11.2.3.1. China Myasthenia Gravis Disease Market Forecast (2017-2027)
11.2.3.2. Japan Myasthenia Gravis Disease Market Forecast (2017-2027)
11.2.3.3. Korea Myasthenia Gravis Disease Market Forecast (2017-2027)
11.2.3.4. India Myasthenia Gravis Disease Market Forecast (2017-2027)
11.2.3.5. Southeast Asia Myasthenia Gravis Disease Market Forecast (2017-2027)
11.2.3.6. Rest of Asia-Pacific Myasthenia Gravis Disease Market Forecast (2017-2027)
11.2.4. South America Myasthenia Gravis Disease Market Forecast (2017-2027)
11.2.4.1. Brazil Myasthenia Gravis Disease Market Forecast (2017-2027)
11.2.4.2. Argentina Myasthenia Gravis Disease Market Forecast (2017-2027)
11.2.4.3. Columbia Myasthenia Gravis Disease Market Forecast (2017-2027)
11.2.4.4. Rest of South America Myasthenia Gravis Disease Market Forecast (2017-2027)
11.2.5. Middle East and Africa Myasthenia Gravis Disease Market Forecast (2017-2027)
11.2.5.1. Saudi Arabia Myasthenia Gravis Disease Market Forecast (2017-2027)
11.2.5.2. United Arab Emirates Myasthenia Gravis Disease Market Forecast (2017-2027)
11.2.5.3. Egypt Myasthenia Gravis Disease Market Forecast (2017-2027)
11.2.5.4. Nigeria Myasthenia Gravis Disease Market Forecast (2017-2027)
11.2.5.5. South Africa Myasthenia Gravis Disease Market Forecast (2017-2027)
11.2.5.6. Turkey Myasthenia Gravis Disease Market Forecast (2017-2027)
11.2.5.7. Rest of Middle East and Africa Myasthenia Gravis Disease Market Forecast (2017-2027)
11.3. Myasthenia Gravis Disease Market Forecast by Diagnosis (2017-2027)
11.3.1. Myasthenia Gravis Disease Forecast by Diagnosis (2017-2027)
11.3.2. Myasthenia Gravis Disease Market Share Forecast by Diagnosis (2017-2027)
11.4. Myasthenia Gravis Disease Market Forecast by Treatment (2017-2027)
11.4.1. Myasthenia Gravis Disease Forecast by Treatment (2017-2027)
11.4.2. Myasthenia Gravis Disease Market Share Forecast by Treatment (2017-2027)
11.5. Myasthenia Gravis Disease Market Forecast by End User (2017-2027)
11.5.1. Myasthenia Gravis Disease Forecast by End User (2017-2027)
11.5.2. Myasthenia Gravis Disease Market Share Forecast by End User (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Myasthenia Gravis Disease Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Myasthenia Gravis Disease Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Myasthenia Gravis Disease Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Myasthenia Gravis Disease Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Myasthenia Gravis Disease Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Myasthenia Gravis Disease Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Myasthenia Gravis Disease Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Myasthenia Gravis Disease Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Myasthenia Gravis Disease Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Myasthenia Gravis Disease Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Myasthenia Gravis Disease Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Myasthenia Gravis Disease Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Myasthenia Gravis Disease Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Myasthenia Gravis Disease Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Myasthenia Gravis Disease Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Myasthenia Gravis Disease Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Myasthenia Gravis Disease Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Myasthenia Gravis Disease Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Myasthenia Gravis Disease Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Myasthenia Gravis Disease Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Myasthenia Gravis Disease Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Myasthenia Gravis Disease Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Myasthenia Gravis Disease Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Myasthenia Gravis Disease Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Myasthenia Gravis Disease Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Myasthenia Gravis Disease Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Myasthenia Gravis Disease Revenue and Revenue Share by Diagnosis (2017-2018)
Figure Global Edrophonium Test Revenue and Growth Rate (2017-2018)
Figure Global Imaging Revenue and Growth Rate (2017-2018)
Figure Global Electrodiagnostic Revenue and Growth Rate (2017-2018)
Figure Global Blood Tests Revenue and Growth Rate (2017-2018)
Table Global Myasthenia Gravis Disease Revenue and Revenue Share by Treatment (2017-2018)
Figure Global HSCT Revenue and Growth Rate (2017-2018)
Figure Global Medication Revenue and Growth Rate (2017-2018)
Figure Global Surgery Revenue and Growth Rate (2017-2018)
Table Global Myasthenia Gravis Disease Revenue and Revenue Share by End User (2017-2018)
Figure Global Hospitals Revenue and Growth Rate (2017-2018)
Figure Global Academic Research Institutes Revenue and Growth Rate (2017-2018)
Figure Global Clinics Revenue and Growth Rate (2017-2018)
Table Global Myasthenia Gravis Disease Revenue by Regions (2017-2018)
Figure North America Myasthenia Gravis Disease Growth Rate (2017-2018)
Figure North America Myasthenia Gravis Disease Revenue and Growth Rate (2017-2018)
Figure North America Myasthenia Gravis Disease by Countries (2017-2018)
Figure North America Myasthenia Gravis Disease Revenue (Million USD) by Countries (2017-2018)
Figure United States Myasthenia Gravis Disease Growth Rate (2017-2018)
Figure United States Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Myasthenia Gravis Disease Growth Rate (2017-2018)
Figure Canada Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Myasthenia Gravis Disease Growth Rate (2017-2018)
Figure Mexico Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Myasthenia Gravis Disease Growth Rate (2017-2018)
Figure Europe Myasthenia Gravis Disease Revenue and Growth Rate (2017-2018)
Figure Europe Myasthenia Gravis Disease by Countries (2017-2018)
Figure Europe Myasthenia Gravis Disease Revenue (Million USD) by Countries (2017-2018)
Figure Germany Myasthenia Gravis Disease Growth Rate (2017-2018)
Figure Germany Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Myasthenia Gravis Disease Growth Rate (2017-2018)
Figure France Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Myasthenia Gravis Disease Growth Rate (2017-2018)
Figure UK Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Myasthenia Gravis Disease Growth Rate (2017-2018)
Figure Russia Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Myasthenia Gravis Disease Growth Rate (2017-2018)
Figure Italy Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Myasthenia Gravis Disease Growth Rate (2017-2018)
Figure Rest of Europe Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Myasthenia Gravis Disease Growth Rate (2017-2018)
Figure Asia-Pacific Myasthenia Gravis Disease Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Myasthenia Gravis Disease by Countries (2017-2018)
Figure Asia-Pacific Myasthenia Gravis Disease Revenue (Million USD) by Countries (2017-2018)
Figure China Myasthenia Gravis Disease Growth Rate (2017-2018)
Figure China Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Myasthenia Gravis Disease Growth Rate (2017-2018)
Figure Japan Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Myasthenia Gravis Disease Growth Rate (2017-2018)
Figure Korea Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Myasthenia Gravis Disease Growth Rate (2017-2018)
Figure India Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Myasthenia Gravis Disease Growth Rate (2017-2018)
Figure Southeast Asia Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Myasthenia Gravis Disease Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Myasthenia Gravis Disease Growth Rate (2017-2018)
Figure South America Myasthenia Gravis Disease Revenue and Growth Rate (2017-2018)
Figure South America Myasthenia Gravis Disease by Countries (2017-2018)
Figure South America Myasthenia Gravis Disease Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Myasthenia Gravis Disease Growth Rate (2017-2018)
Figure Brazil Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Myasthenia Gravis Disease Growth Rate (2017-2018)
Figure Argentina Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Myasthenia Gravis Disease Growth Rate (2017-2018)
Figure Columbia Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Myasthenia Gravis Disease Growth Rate (2017-2018)
Figure Rest of South America Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Myasthenia Gravis Disease Growth Rate (2017-2018)
Figure Middle East and Africa Myasthenia Gravis Disease Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Myasthenia Gravis Disease by Countries (2017-2018)
Figure Middle East and Africa Myasthenia Gravis Disease Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Myasthenia Gravis Disease Growth Rate (2017-2018)
Figure Saudi Arabia Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Myasthenia Gravis Disease Growth Rate (2017-2018)
Figure United Arab Emirates Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Myasthenia Gravis Disease Growth Rate (2017-2018)
Figure Egypt Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Myasthenia Gravis Disease Growth Rate (2017-2018)
Figure Nigeria Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Myasthenia Gravis Disease Growth Rate (2017-2018)
Figure South Africa Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Myasthenia Gravis Disease Growth Rate (2017-2018)
Figure Turkey Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Myasthenia Gravis Disease Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2017-2018)
Table Fresenius Kabi Myasthenia Gravis Disease Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Cipla Myasthenia Gravis Disease Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Valeant Pharmaceuticals International Myasthenia Gravis Disease Price, Revenue, Gross Margin and Market Share (2017-2017)
Table GlaxoSmithKline plc Myasthenia Gravis Disease Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Sun Pharmaceuticals Industries Ltd. Myasthenia Gravis Disease Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Piramal Healthcare Myasthenia Gravis Disease Price, Revenue, Gross Margin and Market Share (2017-2017)
Table AbbVie Inc. Myasthenia Gravis Disease Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Novartis Pharmaceuticals Corporation Myasthenia Gravis Disease Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Biogen Inc. Myasthenia Gravis Disease Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Apotex Corporation Myasthenia Gravis Disease Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Bristol-Myers Squibb Company Myasthenia Gravis Disease Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Teva Pharmaceutical Industries Ltd. Myasthenia Gravis Disease Price, Revenue, Gross Margin and Market Share (2017-2017)
Table F. Hoffmann Roche La Ltd. Myasthenia Gravis Disease Price, Revenue, Gross Margin and Market Share (2017-2017)
Table RPG Life Sciences Myasthenia Gravis Disease Price, Revenue, Gross Margin and Market Share (2017-2017)
Figure Global Myasthenia Gravis Disease Market Share by Manufacturer
Figure Global Myasthenia Gravis Disease Revenue and Market Share by Manufacturer
Table Global Myasthenia Gravis Disease Price by Region (2017-2017)
Figure Top 5 Myasthenia Gravis Disease Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Myasthenia Gravis Disease Revenue (Millions USD) and Growth Rate (2018-2025)
Table Myasthenia Gravis Disease Market Forecast by Regions (2018-2025)
Figure North America Myasthenia Gravis Disease Market Forecast (2018-2025)
Figure United States Myasthenia Gravis Disease Market Forecast (2018-2025)
Figure Canada Myasthenia Gravis Disease Market Forecast (2018-2025)
Figure Mexico Myasthenia Gravis Disease Market Forecast (2018-2025)
Figure Europe Myasthenia Gravis Disease Market Forecast (2018-2025)
Figure Germany Myasthenia Gravis Disease Market Forecast (2018-2025)
Figure France Myasthenia Gravis Disease Market Forecast (2018-2025)
Figure UK Myasthenia Gravis Disease Market Forecast (2018-2025)
Figure Russia Myasthenia Gravis Disease Market Forecast (2018-2025)
Figure Italy Myasthenia Gravis Disease Market Forecast (2018-2025)
Figure Rest of Europe Myasthenia Gravis Disease Market Forecast (2018-2025)
Figure Asia-Pacific Myasthenia Gravis Disease Market Forecast (2018-2025)
Figure China Myasthenia Gravis Disease Market Forecast (2018-2025)
Figure Japan Myasthenia Gravis Disease Market Forecast (2018-2025)
Figure Korea Myasthenia Gravis Disease Market Forecast (2018-2025)
Figure India Myasthenia Gravis Disease Market Forecast (2018-2025)
Figure Southeast Asia Myasthenia Gravis Disease Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Myasthenia Gravis Disease Market Forecast (2018-2025)
Figure South America Myasthenia Gravis Disease Market Forecast (2018-2025)
Figure Brazil Myasthenia Gravis Disease Market Forecast (2018-2025)
Figure Argentina Myasthenia Gravis Disease Market Forecast (2018-2025)
Figure Columbia Myasthenia Gravis Disease Market Forecast (2018-2025)
Figure Rest of South America Myasthenia Gravis Disease Market Forecast (2018-2025)
Figure Middle East and Africa Myasthenia Gravis Disease Market Forecast (2018-2025)
Figure Saudi Arabia Myasthenia Gravis Disease Market Forecast (2018-2025)
Figure United Arab Emirates Myasthenia Gravis Disease Market Forecast (2018-2025)
Figure Egypt Myasthenia Gravis Disease Market Forecast (2018-2025)
Figure Nigeria Myasthenia Gravis Disease Market Forecast (2018-2025)
Figure South Africa Myasthenia Gravis Disease Market Forecast (2018-2025)
Figure Turkey Myasthenia Gravis Disease Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Myasthenia Gravis Disease Market Forecast (2018-2025)
Figure Global Myasthenia Gravis Disease Forecast by Diagnosis (2018-2025)
Figure Global Myasthenia Gravis Disease Market Share Forecast by Diagnosis (2018-2025)
Figure Global Myasthenia Gravis Disease Forecast by Diagnosis (2018-2025)
Figure Global Myasthenia Gravis Disease Forecast by Treatment (2018-2025)
Figure Global Myasthenia Gravis Disease Market Share Forecast by Treatment (2018-2025)
Figure Global Myasthenia Gravis Disease Forecast by Treatment (2018-2025)
Figure Global Myasthenia Gravis Disease Forecast by End User (2018-2025)
Figure Global Myasthenia Gravis Disease Market Share Forecast by End User (2018-2025)
Figure Global Myasthenia Gravis Disease Forecast by End User (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|